CPIX icon

Cumberland Pharmaceuticals

2.27 USD
-0.05
2.16%
At close Dec 20, 4:00 PM EST
After hours
2.23
-0.04
1.76%
1 day
-2.16%
5 days
-1.73%
1 month
108.26%
3 months
86.07%
6 months
57.64%
Year to date
22.70%
1 year
30.46%
5 years
-55.31%
10 years
-58.27%
 

About: Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Employees: 91

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 5

0.16% less ownership

Funds ownership: 14.66% [Q2] → 14.5% (-0.16%) [Q3]

4% less funds holding

Funds holding: 23 [Q2] → 22 (-1) [Q3]

18% less capital invested

Capital invested by funds: $3.18M [Q2] → $2.61M (-$566K) [Q3]

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Research analyst outlook

We haven’t received any recent analyst ratings for CPIX.

Financial journalist opinion

Positive
Benzinga
1 week ago
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
On Monday, the FDA approved Cumberland Pharmaceuticals Inc's  CPIX supplemental New Drug Application (sNDA) for its Acetadote (N-acetylcysteine for injection) product.
Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?
Neutral
PRNewsWire
1 week ago
FDA APPROVES ACETADOTE® sNDA
-  New Dosing Regimen Simplifies Administration  - NASHVILLE, Tenn. , Dec. 9, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced today the FDA has approved a supplemental New Drug Application (sNDA) for its Acetadote® (N-acetylcysteine for injection) product.
FDA APPROVES ACETADOTE® sNDA
Neutral
Seeking Alpha
1 month ago
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.
Cumberland Pharmaceuticals Inc. (CPIX) Q3 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
–        New Real World Study of 150,000 Patients Favors Caldolor over ketorolac   – –        DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations   – NASHVILLE, Tenn. , Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024.
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Neutral
PRNewsWire
1 month ago
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
NASHVILLE, Tenn. , Nov. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare Pediatric Disease Designation to Ifetroban for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
Neutral
PRNewsWire
1 month ago
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
–        Real World Study Compared Over 150,000 Adult & Pediatric Patients – –        Caldolor Associated with Fewer Adverse Drug Reactions – –        Caldolor also Improved Healthcare Utilization – NASHVILLE, Tenn. , Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (Nasdaq: CPIX) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations.
New Study Compares Caldolor® (ibuprofen injection) to ketorolac
Neutral
PRNewsWire
1 month ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , Oct. 31, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2024 financial results and provide a company update after the market closes on Thursday, Nov. 7, 2024.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS
Neutral
Seeking Alpha
4 months ago
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX ) Q2 2024 Results Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Molly Aggas - Investor Relations, Dalton Agency A.J. Kazimi - Chief Executive Officer Todd Anthony - Vice President, Organizational Development John Hamm - Chief Financial Officer Conference Call Participants Operator Good afternoon.
Cumberland Pharmaceuticals Inc. (CPIX) Q2 2024 Earnings Call Transcript
Neutral
PRNewsWire
4 months ago
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
NASHVILLE, Tenn. , Aug. 6, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2024.
Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024
Neutral
PRNewsWire
4 months ago
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
NASHVILLE, Tenn. , July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024.
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
Charts implemented using Lightweight Charts™